Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer's disease

被引:42
作者
Connelly, PJ
Prentice, NP
Fowler, KG
机构
[1] Univ Dundee, Murray Royal Hosp, Dept Psychiat, Perth PH2 7BH, Scotland
[2] Perth Royal Infirm, Perth PH1 1NX, Scotland
关键词
D O I
10.1136/jnnp.2004.043539
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To investigate the possibility that response to cholinesterase inhibitor therapy could be predicted by easily measurable variables that are known to change as a result of treatment (such as the Mini Mental State Examination), measures of function (such as the instrumental activities of daily living and the social behaviour subscales of the Nurse's Observation Scale for Geriatric Patients), and measures of attention (such as the Digit Symbol Substitution Test; DSST), or that might influence response through structural (for example, age, cerebrovascular disease, medial temporal lobe (MTL) atrophy, hypertension) or chemical (for example, smoking) mechanisms. Method: This was a cohort study of 160 consecutive outpatients with probable Alzheimer's disease who commenced cholinesterase inhibitor treatment over a 3 year period in a semi-rural area of Scotland. Results: The overall response rate was 42.1%. Stratification of response between good and poor responders was possible using baseline DSST and a measure of MTL thickness using CT. Among the patients, 60.4% of those above the cut off point for both DSST and MTL thickness (29/48 subjects) were classified as good responders, compared with 6.3% of subjects below the cut off point for both (1/16 subjects). Subjects above the cut off point for both measures were more likely to be classified as good responders than subjects with only one or no values above the respective cut off points (chi(2) = 10.61, df = 1, P = 0.001) Conclusions: The DSST and a measure of MTL thickness derived from CT scanning may be useful in improving the prediction of response to cholinesterase inhibitors in subjects with AD. Subjects with low DSST scores and more severe MTL atrophy are unlikely to respond to treatment. These preliminary data justify a prospective trial of the usefulness of our suggested predictive measures.
引用
收藏
页码:320 / 324
页数:5
相关论文
共 45 条
  • [1] Adler G, 2004, J NEUROL NEUROSUR PS, V75, P292
  • [2] APOE genotype:: No influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease
    Aerssens, J
    Raeymaekers, P
    Lilienfeld, S
    Geerts, H
    Konings, F
    Parys, W
    [J]. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2001, 12 (02) : 69 - 77
  • [3] PSYCHOMETRIC DISCRIMINATION OF TETRAHYDROAMINOACRIDINE RESPONDERS IN ALZHEIMER PATIENTS
    ALHAINEN, K
    HELKALA, EL
    RIEKKINEN, P
    [J]. DEMENTIA, 1993, 4 (01): : 54 - 58
  • [4] WHITE-MATTER HYPERINTENSITY AND NEUROPSYCHOLOGICAL FUNCTIONS IN DEMENTIA AND HEALTHY AGING
    ALMKVIST, O
    WAHLUND, LO
    ANDERSSONLUNDMAN, G
    BASUN, H
    BACKMAN, L
    [J]. ARCHIVES OF NEUROLOGY, 1992, 49 (06) : 626 - 632
  • [5] Responder characteristics to a single oral dose of cholinesterase inhibitor:: A double-blind placebo-controlled study with tacrine in Alzheimer patients
    Almkvist, O
    Jelic, V
    Amberla, K
    Hellström-Lindahl, E
    Meurling, L
    Nordberg, A
    [J]. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2001, 12 (01) : 22 - 32
  • [6] The effects of donepezil in Alzheimer's disease -: Results from a multinational trial
    Burns, A
    Rossor, M
    Hecker, J
    Gauthier, S
    Petit, H
    Möller, HJ
    Rogers, SL
    Friedhoff, LT
    [J]. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 1999, 10 (03) : 237 - 244
  • [7] Cohen J., 1988, STAT POWER ANAL BEHA
  • [8] Evans M, 2000, INT J GERIATR PSYCH, V15, P50
  • [9] Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression
    Farlow, MR
    Hake, A
    Messina, J
    Hartman, R
    Veach, J
    Anand, R
    [J]. ARCHIVES OF NEUROLOGY, 2001, 58 (03) : 417 - 422
  • [10] FARLOW MR, 1998, NEUROBIOLAGING SS, V4, P1264